Invesco Ltd. Buys 4,468 Shares of Amedisys, Inc. $AMED

Invesco Ltd. boosted its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 4.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 95,315 shares of the health services provider’s stock after acquiring an additional 4,468 shares during the quarter. Invesco Ltd. owned about 0.29% of Amedisys worth $8,829,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AMED. Pentwater Capital Management LP boosted its position in shares of Amedisys by 178.3% during the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock valued at $107,132,000 after buying an additional 756,000 shares during the period. AQR Arbitrage LLC boosted its position in shares of Amedisys by 59.1% during the fourth quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider’s stock valued at $42,812,000 after buying an additional 175,311 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Amedisys in the fourth quarter valued at approximately $15,801,000. CIBRA Capital Ltd boosted its holdings in shares of Amedisys by 359.7% in the first quarter. CIBRA Capital Ltd now owns 216,775 shares of the health services provider’s stock valued at $20,080,000 after purchasing an additional 169,616 shares during the period. Finally, Gotham Asset Management LLC boosted its holdings in shares of Amedisys by 77.4% in the fourth quarter. Gotham Asset Management LLC now owns 246,918 shares of the health services provider’s stock valued at $22,418,000 after purchasing an additional 107,720 shares during the period. 94.36% of the stock is owned by institutional investors.

Amedisys Stock Up 0.0%

Amedisys stock opened at $101.01 on Monday. The business has a fifty day moving average of $98.47 and a two-hundred day moving average of $95.06. The company has a quick ratio of 1.36, a current ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm has a market cap of $3.32 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.34 and a beta of 0.89. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $101.02.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.15. The company had revenue of $621.86 million during the quarter, compared to analyst estimates of $614.61 million. Amedisys had a return on equity of 12.91% and a net margin of 3.56%.Amedisys’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.98 earnings per share. On average, analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Amedisys has a consensus rating of “Moderate Buy” and an average target price of $100.50.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.